NASDAQ:APRE
Aprea Therapeutics Inc. Stock Company Profile
$5.14
-0.0350 (-0.677%)
At Close: May 08, 2024
Information
535 Boylston St.
Boston MA 02116
617-463-9385
atrinpharma.com
Industry: Biotechnology
Sector: Healthcare
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.